Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6724956 | 0.83 | ENPP2 (0.38) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL7250626 | 0.78 | LMNA (0.36) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL10995220 | 0.76 | HPGD (0.42) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL6594060 | 0.75 | LMNA (0.33) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL24152095 | 0.74 | LMNA (0.38) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL10982209 | 0.74 | HPGD (0.40) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL6593391 | 0.73 | LMNA (0.34) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL8555144 | 0.71 | MAPT (0.36) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL10411538 | 0.70 | LMNA (0.34) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL9706681 | 0.70 | LMNA (0.35) | LMNAMAPTHPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | CBR1, CBR3, QSOX1 | LMNA 3553/4885MAPT 4497/4885HPGD 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.